Literature DB >> 34013867

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.

Mariana M Lanata, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, Amy Leber.   

Abstract

Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae-positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens.

Entities:  

Keywords:  Mycoplasma pneumoniae; Ohio; United States; antimicrobial resistance; bacteria; children; community-acquired pneumonia; disease severity; macrolide resistance; macrolide sensitivity; molecular detection; pneumonia; respiratory infections

Year:  2021        PMID: 34013867     DOI: 10.3201/eid2706.203206

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  5 in total

1.  Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.

Authors:  Tanner E Rothstein; Scott A Cunningham; Rachelle A Rieke; Jill M Mainella; Melissa M Mutchler; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

2.  Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.

Authors:  Soojeong Choo; Yun Young Lee; Eun Lee
Journal:  BMC Pulm Med       Date:  2022-05-30       Impact factor: 3.320

Review 3.  Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae.

Authors:  Tomohiro Oishi; Kazunobu Ouchi
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

4.  Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia.

Authors:  Soojeong Choo; Seo-Hee Kim; Eun Lee
Journal:  BMC Infect Dis       Date:  2022-05-16       Impact factor: 3.090

5.  Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.

Authors:  Kyunghoon Kim; Sungsu Jung; Mina Kim; Suyeon Park; Hyeon-Jong Yang; Eun Lee
Journal:  JAMA Netw Open       Date:  2022-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.